SK Bioscience, a biotechnology research services firm, agreed to acquire a 60% stake in IDT Biologika, an innovative company in researching, developing, manufacturing and marketing products for the global protection of human and animal health, from Klocke Gruppe, a group of consolidated companies, working in the field of contract manufacturing and contract packaging, for $244m. “We look forward to working with SK bioscience. IDT Biologika has built up an excellent reputation in the field of viral vaccines in recent years and has a reliable business with top pharmaceutical companies as well as government agencies worldwide. SK bioscience is also pursuing this strategy and has extensive expertise in the development and production of vaccines, enabling us to jointly expand our market position. It is equally important that SK bioscience is focusing on the cell and gene therapy segment, just like IDT, and would like to strategically accompany customers in this business area into the future together with IDT Biologika,” Ulrich Valley, IDT Biologika CEO.